Success Stories: EB1A Approval was Achieved in 6 Months and 17 Days for a Chinese Instructor in the Field of Medicinal Chemistry
Client’s Testimonial:
“Really appreciate your efforts working on my case I didn't expect the case approved without RFE. Definitely will recommend WeGreen to my friends seeking immigration services. Thank you!”
On February 21st, 2023, we received another EB-1A (Alien of Extraordinary Ability) approval for an Instructor in the Field of Medicinal Chemistry (Approval Notice).
General Field: Medicinal Chemistry
Position at the Time of Case Filing: Instructor
Country of Origin: China
State of Residence at the Time of Filing: Arkansas
Approval Notice Date: February 21st, 2023
Processing Time: 6 months, 17 days (Premium Processing Requested)
Case Summary:
Our client, an extraordinary researcher who seeks to enter the United States to continue work in the field of medicinal chemistry, approached North America Immigration Law Group to file his EB1A (Alien of Extraordinary Ability) petition. As the expert testimonials and supporting documents demonstrate his extraordinary ability by sustained international acclaim, and his achievements have been recognized in the field through implementation by others and extensive citations of his work. We noted that his impressive background, strong record of past achievements, recognition of expertise by journals seeking his services to review manuscripts, and unique knowledge relevant to his current and future work indicate not only that he qualifies as an alien of extraordinary ability but also that his entry will substantially benefit the United States.
When we agreed to take his case and organize a customized EB1A petition for him leading to the victory, we added the following relevant points in his petition packet:
- Our client is one of the few leading experts in medicinal chemistry, and he has achieved a consistent and notable record of success and influence in this area of study. With a Ph.D. in medicinal chemistry, he focused on generating new ways of treating a variety of cancers and associated diseases. As such, he stands above his peers concerning his prodigious contributions to the field.
- We discovered that his research addresses some of the world’s most pressing issues, including the mortal threat posed by cancer. Therefore, with 20 peer-reviewed scientific articles and 3 patent application publications, he has certainly been a major contributor to the medicinal chemistry community for several years now.
- Additionally, his overall work has been cited 237 times by his peers in at least 33 countries, setting him apart from his peers. Moreover, he is an exceptional researcher at the top of the field of medicinal chemistry, and his findings have considerably impacted many others in the scientific community, thus, he was regularly invited to judge other expert’s work. He conducted at least 20 reviews for highly discerning journals with very stringent publishing guidelines that enlist the services of only the most accomplished researchers.
“Scholars from a diverse set of countries have referenced [the client’s] work in their own, including experts from Ireland, India, Portugal, Pakistan, and Italy. The fact that his research has attained a global reach is a mark of excellence. He is thus an active member of the global community of researchers endeavoring to find solutions for cancer, and his citation record clearly demonstrates the wide-reaching impact of his findings.”
Since cancer treatments are considerably costly as medical expenses. The costs associated with treating cancer impose enormous economic burdens on nearly every country in the world. Our client is a researcher whose work not only improves cancer patient outcomes by developing more efficient methods for developing drugs but also reduces the costs associated with producing these drugs. This is one of the major reasons that the adjudicating authorities at USCIS approved his case in just 19 days after our client upgraded his EB1A case to premium processing. Despite waiting for 6 months, our client achieved EB1A approval without any RFE issuance. Thus, we are glad that our client trusted our law and cooperated with us throughout. We wholeheartedly congratulate him on accomplishing this milestone.